Vanguard Asset Management’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$728K Buy
21,659
+3,127
+17% +$135K ﹤0.01% 2006
2026
Q2
$772K Hold
18,532
– – ﹤0.01% 2010
2026
Q1
$580K Buy
+18,532
New +$521K ﹤0.01% 2025

Other funds holding RAPP

Vanguard Asset Management's RAPP Position: Q3 2026 in Review

Vanguard Asset Management increased its Rapport Therapeutics (RAPP) stake by 17% in Q3 2026, buying an estimated $135K and bringing the position to 21,659 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Vanguard Asset Management first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $772K in Q2 2026. 168 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Vanguard Asset Management held 21,659 shares of Rapport Therapeutics worth $728K as of Q3 2026.
  • Vanguard Asset Management bought 3,127 Rapport Therapeutics shares in Q3 2026, an estimated $135K.
  • Rapport Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2006 holding.
  • Vanguard Asset Management first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Rapport Therapeutics position peaked at $772K in Q2 2026.
  • 168 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.